PHARMATHER

Pharmaceutical 3D Printing for Medicines

pharmather.com

Corporate Presentation · November 2026

CSE: PHRM | OTCQB: PHRRF

Forward-Looking Statements

This presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation with respect to PharmaTher Holdings Ltd. (the “Company”). All information other than statements of historical fact is forward-looking information, including statements regarding: the Company’s corporate strategy and business model; the M3DICINES™ platform and brand; the M3DICINES™ National Network Program, including the enrollment of Network Partners, the terms on which CraftMake™ systems are placed in the network and the expectation that nodes will generate product, licensing, white-label, CDMO, consumables, service, research and government revenue; the commercial plan for CraftMake™, including initial orders, the target of up to 50 placements over the next 12 months, the estimated number of potential placement sites and the expectation that placements will generate recurring revenue; the development, launch timing and commercialization of the Company’s 503A products, including Rx wellness, peptide and longevity products, and the potential compounding of additional peptides following FDA rulemaking; the Company’s FDA rare pediatric disease program for 3D-printed creatine monohydrate in GAMT deficiency, including the FDA’s review of, and decisions on, the Company’s Orphan Drug and Rare Pediatric Disease Designation applications, a pre-IND meeting, clinical development, the timing of an NDA submission, potential approval, orphan exclusivity and potential eligibility for, award of and sale value of a priority review voucher; the evaluation and potential development of products for ultra-rare diseases; plans to supply psychedelic medicines for clinical trials and special access programs; plans to identify and reintroduce discontinued medicines and to make medicines in short supply; the planned National Emergency Preparedness Node Network, its demonstration and potential readiness contracts; partnering opportunities, including CDMO services, white-label products, formulation licensing and research collaborations; the timing and amount of payments from the sale of the Company’s ketamine ANDA; the potential licensing, sale, partnering or spin-out of strategic assets; anticipated market growth; and upcoming milestones and catalysts. Forward-looking information is based on management’s current expectations, estimates and assumptions, including that Craft Health, PD Labs and the Company’s GMP manufacturing and other partners will perform as expected, that Network Partners will join the network on acceptable terms, that the Company will maintain its exclusive distribution rights and obtain financing on acceptable terms, and that regulatory frameworks will develop as expected. It is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied, including the risks that Network Partners may not join the network or placements may not generate the expected revenue, that expanding the network requires capital that may not be recovered, that compounding is subject to substance eligibility under Section 503A and state pharmacy laws, that there is no finalized FDA framework for distributed pharmaceutical manufacturing, that government funding and procurement are uncertain, that the FDA may not grant either designation or may require more evidence than anticipated, that clinical development may not succeed or may take longer or cost more than expected, that regulatory approval may not be obtained, and that a priority review voucher may not be awarded or sold on attractive terms, including because the rare pediatric disease priority review voucher program is currently authorized only through September 30, 2029. No assurance can be given that any of the events anticipated will occur or, if they do, what benefits the Company will derive from them. Product candidates described in this presentation are at a development stage; they are investigational and have not been approved by the FDA, Health Canada or any other regulator. Compounded drugs are not FDA-approved, and certain peptides, including BPC-157, may not be compounded unless and until the FDA completes the applicable rulemaking. Ketamine, psilocybin and MDMA are controlled substances. Program cost and timing figures are internal estimates. Voucher sale prices are taken from public disclosures by the companies involved and have not been independently verified. Market, industry and third-party data have not been independently verified by the Company. This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction. Readers are cautioned not to place undue reliance on forward-looking information and should review the Company’s public filings on SEDAR+ (www.sedarplus.ca) for a full discussion of risk factors. The Company undertakes no obligation to update forward-looking information except as required by law.

CraftMake™, CraftControl™ and CraftBlends™ are trademarks of Craft Health. M3DICINES™ is a trademark of PharmaTher Holdings Ltd. KetaMist® is a trademark of its owner.

About Us

M3DICINES™ Technology Platform


CraftMake™ 3D printer · Novel oral formulations

Two Delivery Platforms

Colon-targeted pills and oral films (BPC-157 and KPV)

Partnering

In-house 3D printing · CDMO · Alliances · Licensing



CraftMake™ by Craft Health



Pill-in-pill



Oral films



Multi-layer tablets



Pellets

Market Opportunity → A large market that mass production cannot serve

Peptides are a fast-growing market, but most must be injected. Printed oral peptides fill that gap.

$567B → $1.2T

Personalized-medicine market, 2024 → 2033

$141B → $295B

Peptide therapeutics market, 2025 → 2033

The Problem

One size fits all. Mass-produced pills leave out children, seniors, rare diseases and personalized doses.

Peptides don't survive the stomach. Acid and enzymes break them down (under 1% absorbed when swallowed), so most are injected.

The Solution

Print the exact dose for one patient, on demand, at a pharmacy near them.

Protect the peptide. Our pill-in-pill carries it past the stomach to the colon; our oral film delivers it through the cheek lining.


Opportunity Window


Regulators are opening the door to compounded peptides and printed medicines.

New: HHS now lets 503A pharmacies compound six peptides, including KPV and BPC-157 (Oct. 2026).

Sources: Figures in USD. Grand View Research (Personalized Medicine; Peptide Therapeutics market reports); FDA PCAC, July 2026; HHS policy notice, Docket HHS-OASH-2026-0496 (Oct. 2026). Oral bioavailability: Mantaj & Vllasaliu, The Pharmaceutical Journal (2020). Market data not independently verified by the Company.

Why 3D Printing of Medicines → where mass production can not do economically





Batch size	Pays off only at millions of units	→	**Economic from tens to thousands of units**
Dose	A few fixed strengths; patients split pills	→	**Any dose, ±1% accurate, from one recipe**
Pill design	One medicine, one release speed	→	**Several medicines and release speeds in one pill**
Process	Heat, pressure or UV; hard on peptides	→	**Room temperature; peptides stay intact**
Location	Central plants, often overseas	→	**Locally: a pharmacy, hospital or node**


Dose accuracy and room-temperature process per Craft Health platform specifications. Images: the mass-production scene is an illustration; CraftMake™, gummy and tablet images courtesy of Craft Health; the pill-in-pill is a render.

Our Solution


M3DICINES™ 3D-Printed Medicines Platform

Precise, room-temperature (no heat, no UV) printing of customized doses on GMP-ready CraftMake™.

CRAFTMAKE™ 3D PRINTER




CRAFTCONTROL™ SOFTWARE




No-code dose templates · audit trail · multi-printer

DOSAGE FORMS



Pill-in-pill tablets



Gummies & chewables




Pellets & mini-tablets



Multi-layered tablets



Liquid-embedded chewables



Liquid-core chewables



Multi-layered capsules



Oral dissolvable films

RELEASE PROFILES

Immediate · Sustained · Delayed · Colon-targeted · Enhanced solubility · Gastro-retentive

PATENT PORTFOLIO

Owned by Craft Health

4 patent families

3 granted · U.S. and Japan

4 pending · U.S. and U.K.


Covers: colon-targeted, long-release and poorly soluble actives

Images: Craft Health platform-capability imagery, including the CraftControl™ software photo, shared with PharmaTher under the companies' collaboration and distribution agreements. ±1% dose precision and >95% repeatability per Craft Health specifications. Patents owned by Craft Health (granted: US 12,544,310; JP 7525935; JP 7624750), status at Oct. 16, 2026; PharmaTher holds exclusive North American distribution rights.

Business Model

Our MOAT: exclusive CraftMake™ rights plus our own oral peptide formulations, made possible only by 3D printing.

1 PEPTIDES ON TWO PLATFORMS



BPC-157 and KPV

On a colon-targeted pill-in-pill and a mucoadhesive oral film.

SOLD TO

Patients, through pharmacies and partner platforms


HOW IT WORKS

Prescription → **PD Labs prints** → **Shipped home** → **Refills**

HOW WE EARN

Peptide product sales
Recurring refills for each patient

2 CRAFTMAKE™ PARTNERING



CraftMake™ 3D printing

Exclusive North American rights to the printer, software and formulations.

SOLD TO

Pharmacies, hospitals, labs, pharma/biotech and brands

WHAT WE OFFER

- **Placements** — Pharmacies, hospitals, labs
- **CDMO and white-label** — Partner brands
- **Business development** — Alliances, licensing

HOW WE EARN


Placements, consumables and service
Development fees, licences and royalties

Two Delivery Platforms

Colon-targeted peptides (BPC-157 and KPV): first in line for a new U.S. peptide market

HHS opened a peptide pathway in Oct. 2026; only KPV and BPC-157 are covered for oral use.

HOW IT WORKS · A PILL-IN-PILL THAT OPENS IN THE COLON



1 Enteric shell
Printed layers that open only above pH 7, near the colon

2 Inner pill
The patient's dose, released at once when the shell opens

3 Sealed base
The same enteric polymer closes the bottom

Printed, not coated: CraftMake™ prints the shell and the inner pill together, at room temperature, in under 1.5 minutes per tablet.

Stomach → Acid can't open the shell

Small intestine → Still sealed

Colon → Shell opens; dose released where it is needed

12,000×
lower KPV dose gave a similar effect when delivered to the colon (mouse colitis study)

Up to 75%
of the dose reached a simulated colon, vs. under 10% for a commercial product (in vitro)

OUR OPPORTUNITY, OUR MOAT

A new market just opened
HHS's Oct. 2026 policy lets 503A pharmacies compound six peptides; **only KPV and BPC-157 for oral use.**

A clear unmet need
30–60% of ulcerative colitis patients have disease in the lower colon, which most oral budesonide products aren't designed to reach.

Hard to copy
Patent-pending CORR3CT™ design and exclusive North American CraftMake™ rights. No heat, so fragile peptides stay intact.

Ready to sell through partners
For pharmacies and partner platforms with patients.

$29.6B
global IBD treatment market, 2025

$141B
peptide therapeutics market, 2025

600–900K
Americans with ulcerative colitis

Animal (mouse colitis) and in vitro (budesonide model) data; results in humans are not established. Compounded peptides are not FDA-approved; the HHS policy is interim and may be revised or applied differently by states. No efficacy claims are made. Image: render of the CORR3CT™ budesonide tablet built to its published dimensions (Ou, Goh & Lim, Int J Pharm 2023;635:122680); GI journey is illustrative. Sources: PharmaTher news release, Oct. 29, 2026; HHS policy notice (Docket HHS-OASH-2026-0496); Grand View Research; NIDDK. Market data not independently verified by the Company.

Mucoadhesive Oral Films

Our second delivery platform, in development: printed films for systemic delivery.



HOW IT WORKS

1 Printed to the dose

Printed on CraftMake™ at room temperature from a digital recipe; the size of the film sets the dose.

2 Placed on the inner cheek

A two-layer film: the mucoadhesive layer holds the dose against the cheek; the backing layer faces the mouth.

3 Into the bloodstream

The dose passes through the cheek lining, bypassing the stomach, gut and first-pass liver metabolism.

Two platforms, one pipeline: BPC-157 and KPV are being developed on both the colon-targeted pill-in-pill and the oral film.

$141B → $295B
Peptide therapeutics market, 2025 → 2033

Under 1%
of a peptide dose absorbed when swallowed

2
peptides on both platforms: BPC-157 and KPV

Concept render. The oral film is an early-stage development program and is not available; its formulation, performance and regulatory pathway have not been established, including whether the HHS policy's oral-use coverage applies to buccal delivery. Compounded products are not FDA-approved. No efficacy claims are made. Sources: Grand View Research (Peptide Therapeutics); Mantaj & Vllasaliu, The Pharmaceutical Journal (2020). Market data not independently verified by the Company.

Partnership Opportunities

Exclusive North American Rights to CraftMake™

10,000+ potential sites across North America.




CraftMake™

3D printing system by Craft Health

GMP-READY

ROOM TEMP · NO HEAT, NO UV

±1% PRECISION · >95% REPEATABILITY



Every placement is infrastructure, not a one-time sale.

Each system keeps earning and can support PharmaTher and partner programs: brands, R&D and national emergencies.

POTENTIAL PARTNERS & CUSTOMERS

503A compound pharmacies
~7,500 U.S. 503A pharmacies alone

Consumer health and wellness brands
White-label products and manufacturing

CDMOs, pharma and biotech
Clinical supply and production


Hospitals and health systems
Pediatric and special-population doses

Academic and research labs
Feasibility and validation studies

Government and defence
Preparedness and countermeasures

Placement estimate is a management estimate and forward-looking; nodes require site qualification. CraftMake™ is a Craft Health product; specifications per Craft Health. Network map is illustrative.


Ways to work with us



Bring 3D printing in-house

For pharmacies, hospitals, CDMOs and labs.


Printer, software, training and service included.



Let us make it

For pharma, biotech and government.

Feasibility studies, clinical trial supply and small-batch production through PD Labs and our GMP partner.



Build a product together

For consumer-health and pharma brands.

White-label products, co-development, joint ventures, alliances and licensing of our formulations.

Commercial infrastructure

Craft Health

TECHNOLOGY

Exclusive North American distributor

CraftMake™ systems, software, materials and service. Every placement seeds recurring revenue and runs M3DICINES™ formulations.

pdlabs
prescription dispensing laboratories

DISPENSING AND R&D

Center of Excellence

PD Labs: a U.S. national 503A compounding pharmacy with 26+ years of experience, for dispensing and R&D.

MANUFACTURING

GMP contract manufacturer

FDA-track products and CDMO services, including clinical trial supply.

Beyond the core → monetization opportunities

Ketamine and Cepharanthine

Available to partner, license or sell: KetaVault™, ketamine patch, KetaMist®, 49% of Sairiyo.

GAMT deficiency

3D-printed creatine for a rare childhood disease. FDA designation decisions Q1 2027; approval could earn a voucher (recent sales US$150–200M).

Pediatrics, deprescribing

Programs that reuse the peptide formulation library, software and pharmacy network.

Nutraceuticals, pet health, reformulated drugs

Partner-branded products printed on the same CraftMake™ network.

Rare, psychedelic and discontinued medicines

Small-batch medicines a production line cannot serve economically.


Emergency-preparedness network

Qualified nodes print countermeasures locally; readiness contracts pursued with ASPR and DRDC.

Forward-looking; these programs advance only as partners and funding allow. The FDA may not grant designations, and a voucher may not be awarded or sold. Readiness contracts are prospective. Compounded and investigational products are not FDA-approved. Voucher sales: Abeona US$155M (Jun 2025), Jazz US$200M (Jan 2026).

Expected Milestones

Peptide launches, CraftMake™ placements and partner agreements.



Milestones and timelines are internal targets and forward-looking statements; they may change. Compounded products are not FDA-approved; peptide launches depend on the HHS policy conditions and state rules.

Leadership → drug development, FDA approvals, compound pharmacy and commercialization

MANAGEMENT & BOARD



Fabio Chianelli

Founder, Chairman & CEO

25+ years in specialty life sciences and investing; founder of PharmaTher and Revive Therapeutics.



Carmelo Marrelli

Chief Financial Officer

Public-company finance and administration; principal of Marrelli Support Services since 2009.



Dr. Beverly J. Incledon

Director

30+ years in pharma and drug delivery; former EVP R&D at Ironshore Pharmaceuticals.

CS

Carlo Sansalone

Director

Investor across biotech, technology and real estate; President at Sanscon.

PARTNER LEADERSHIP



Ray Solano

Founder & President, PD Labs

Clinical pharmacist for 35 years and certified clinical nutritionist; PD Labs is PharmaTher's U.S. 503A Center of Excellence.



Dr. Wei Jiang Goh

Co-founder & CEO, Craft Health

Pharmacist; co-founder of Craft Health, maker of CraftMake™. PhD and MBA, National University of Singapore.



Dr. Seng Han Lim

Co-founder & COO, Craft Health

Pharmacist; co-founder of Craft Health. PhD in pharmacy (NUS) focused on 3D-printed personalized dosage forms.

Capital structure

As at September 30, 2026

91,019,065

Issued and outstanding common shares

1,500,000

Stock options outstanding

~19%

Insider ownership

PHRM

Canadian Securities Exchange (CSE)

PHRRF

OTCQB Venture Market (U.S.)

PHARMATHER

Thank You

info@pharmather.com · 1-888-846-3171

pharmather.com